According to the Hairong Cold Chain announcement, the company plans to use its own funds to provide financial support of 20 million yuan to the holding subsidiary Qingdao Hairong Huikang Biomedical Holdings Co., Ltd., for a period of 3 years. Interest will be calculated according to the bank loan benchmark interest rate for the same period. The matter was identified as a related transaction because other shareholders involved related parties. At the same time, the company disclosed the profit distribution plan for the first three quarters of 2026. It plans to distribute a cash dividend of 2.00 yuan for every 10 shares based on the total share capital on the share registration date, with no bonus shares or additional share capital. In total, it plans to distribute a cash dividend of about 77.2795 million yuan. The above two bills will be submitted to the 2nd Extraordinary Shareholders' Meeting in 2026 for consideration.

According to the Hairong Cold Chain announcement, the company plans to use its own funds to provide financial support of 20 million yuan to the holding subsidiary Qingdao Hairong Huikang Biomedical Holdings Co., Ltd., for a period of 3 years. Interest will be calculated according to the bank loan benchmark interest rate for the same period. The matter was identified as a related transaction because other shareholders involved related parties. At the same time, the company disclosed the profit distribution plan for the first three quarters of 2026. It plans to distribute a cash dividend of 2.00 yuan for every 10 shares based on the total share capital on the share registration date, with no bonus shares or additional share capital. In total, it plans to distribute a cash dividend of about 77.2795 million yuan. The above two bills will be submitted to the 2nd Extraordinary Shareholders' Meeting in 2026 for consideration.